Sansone Randy A, Sansone Lori A
R. Sansone is a professor in the Departments of Psychiatry and Internal Medicine at Wright State University School of Medicine in Dayton, OH, and Director of Psychiatry Education at Kettering Medical Center in Kettering, OH. L. Sansone is a civilian family medicine physician at the Primary Care Clinic at Wright-Patterson Air Force Base in Dayton, OH. The views and opinions expressed in this article are those of the authors and do not reflect the official policy or position of the United States Air Force, Department of Defense, or United States Government.
Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):32-6.
While most clinicians will never prescribe buprenorphine or combined buprenorphine/naloxone, familiarity with the risks of these pharmacological approaches to the treatment of narcotic addiction remains relevant. Overall, medication-assisted treatment has clearly resulted in meaningful gains for a number of individuals who are addicted to narcotics (i.e., opiates and opioids). However, a certain level of risk is inherent with these approaches. For example, both buprenorphine and buprenorphine/naloxone may be diverted and misused (e.g., intravenously injected, intranasally administered), particularly buprenorphine. Likewise, when illicitly injected, both can cause infectious complications as well as result in death from overdose. The risk of death with buprenorphine overdose appears to be heightened with the coadministration of either benzodiazepines or sedative/hypnotics. To conclude, as with all interventions in medicine, buprenorphine treatment for narcotic addiction has a clinically fluctuating risk/benefit equation that must be continually monitored.
虽然大多数临床医生永远不会开具丁丙诺啡或丁丙诺啡/纳洛酮复方制剂,但了解这些用于治疗麻醉品成瘾的药理学方法的风险仍然很有必要。总体而言,药物辅助治疗显然已使许多对麻醉品(即阿片类和阿片样物质)成瘾的人取得了显著成效。然而,这些方法存在一定程度的固有风险。例如,丁丙诺啡和丁丙诺啡/纳洛酮都可能被转移和滥用(如静脉注射、鼻内给药),尤其是丁丙诺啡。同样,非法注射时,两者都可能导致感染并发症以及因过量用药而死亡。丁丙诺啡过量用药导致死亡的风险在同时使用苯二氮䓬类药物或镇静/催眠药时似乎会增加。总之,与医学中的所有干预措施一样,丁丙诺啡治疗麻醉品成瘾的临床风险/效益平衡存在波动,必须持续监测。